Acthar

Mallinckrodt PLC (NYSE: MNK) shares are ripping higher Tuesday after the company announced a global opioid settlement agreement that limits its payout to $1.6 billion and it aslo reported better-than-expected fourth-quarter results. Opioid Settlement Clinched, Generics Business To File For Chapter...

Biopharmaceutical company Mallinckrodt plc (NYSE: MNK) said Wednesday it reached an agreement in principle with the Department of Justice relating to "legacy sales and marketing activites" by its Questcor subsidiary.  The company said it expects to pay $15.4 million...

Biopharmaceutical company Mallinckrodt plc (NYSE: MNK)'s shares lost about 25 percent of their value Tuesday following news that the company filed suit against the Department Of Health And Human Services and Centers for Medicare and Medicaid Services to challenge the level of Medicaid...

A Canaccord Genuity analyst came away from a meeting with Mallinckrodt PLC (NYSE: MNK)'s executive team with an upbeat forecast for the pharma company's near-term prospects.  The Analyst Analyst Dewey Steadman upgraded Mallinckrodt from Hold to Buy and increased the price target...

Mallinckrodt PLC (NYSE: MNK) agreed to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) in a deal announced in December. The Analyst Weighing in the planned acquisition, Barclays analyst Douglas Tsao downgraded shares of Mallinckrodt from Equal Weight to Underweight and lowered the price...

After completing a sum-of-the-parts analysis, UBS analyst Marc Goodman still sees Mallinckrodt PLC (NYSE: MNK) as a strong risk/reward play. Goodman maintained his Buy rating and 12-month $70 price target. “The key overhang for the stock remains the sustainability of Acthar, particularly from...

Oppenheimer remains Outperform-rated on Mallinckrodt PLC (NYSE: MNK) saying near-term concerns over Acthar competition are overblown, as he expressed confidence in Acthar's durability. The brokerage, which has a $72 price target on Mallinckrodt shares, said the company’s key brands,...

Shares of Mallinckrodt PLC (NYSE: MNK) sold off Wednesday after Citron Research released a new thesis on the maligned pharmaceutical company. The new report valued the stock at $20 and alleged the company "has committed fraud [emphasis omitted] by lying to the investing public about the...

Mallinckrodt PLC (NYSE: MNK) shares plummeted 37 percent, declining steeply from August through November. Oppenheimer’s Akiva Felt maintained an Outperform rating on the company, with a price target of $138. Two Acthar data presentations demonstrating early, yet impressive responses...

David Buck of Northland Capital Markets initiated coverage of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Mallinckrodt PLC (NYSE: MNK), and Shire PLC (ADR) (NASDAQ: SHPG) with Outperform ratings. Buck is positive on the long-term revenue prospect of the three names. Buck noted all three...

Aetna (NYSE: AET) said on Wednesday that it would limit coverage of a multiple sclerosis and infant seizure drug from Questcor Pharmaceuticals (NASDAQ: QCOR). The news caused shares of Questcor to plunge as much as 56 percent in morning trading, the largest one-day drop for the stock since 1993. At...